Patents by Inventor Marc Adler

Marc Adler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11339130
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: May 24, 2022
    Assignee: Blade Therapeutics, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Shendong Yuan, Marc Adler, Kumaraswamy Emayan, Jingyuan Ma
  • Patent number: 11292801
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic ?-keto amide derivatives and their use as therapeutic agents.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: April 5, 2022
    Assignee: Blade Therapeutics, Inc.
    Inventors: Brad Owen Buckman, Shendong Yuan, John Beamond Nicholas, Jingyuan Ma, Kumaraswamy Emayan, Marc Adler
  • Publication number: 20210347727
    Abstract: Small molecule calpain modulator compositions and pharmaceutical compositions can be prepared and used as therapeutic agents. Exemplary compositions include non-macrocyclic a-keto amide derivatives. The therarapeutic agents can be used for treating fibrotic disease or a resulting secondary disease state or condition. The small molecules can competitively bind with calpastatin and/or inhibit calpain through contact with CAPN1, CAPN2, and/or CAPN9 enzymes.
    Type: Application
    Filed: June 19, 2018
    Publication date: November 11, 2021
    Inventors: Brad Owen Buckman, Shendong Yuan, John Beamond Nicholas, Jingyuan Ma, Kumaraswamy Emayan, Marc Adler
  • Publication number: 20210261587
    Abstract: Disclosed herein, inter alia, are compounds for binding STRAD pseudokinase and uses thereof.
    Type: Application
    Filed: January 28, 2021
    Publication date: August 26, 2021
    Inventors: John Gordan, Dominique Mitchell, Richard Beresis, Marc Adler
  • Publication number: 20210238192
    Abstract: Disclosed herein are small molecule Vascular Adhesion Protein-1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Application
    Filed: June 27, 2019
    Publication date: August 5, 2021
    Inventors: Brad Owen Buckman, Prabha Ibrahim, Shendong Yuan, Kumaraswamy Emayan, Marc Adler
  • Patent number: 10934261
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: March 2, 2021
    Assignee: Blade Therapeutics, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Shendong Yuan, Marc Adler, Kumaraswamy Emayan, Jingyuan Ma
  • Patent number: 10894776
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: January 19, 2021
    Assignee: Blade Therapeutics, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Shendong Yuan, Marc Adler, Kumaraswamy Emayan, Jingyuan Ma
  • Publication number: 20210009564
    Abstract: Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.
    Type: Application
    Filed: March 21, 2019
    Publication date: January 14, 2021
    Inventors: Brad Owen Buckman, Shendong Yuan, Kumaraswamy Emayan, Marc Adler, Prabha Ibrahim
  • Publication number: 20200392157
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic ?-keto amide derivatives and their use as therapeutic agents.
    Type: Application
    Filed: June 29, 2017
    Publication date: December 17, 2020
    Inventors: Brad Owen Buckman, Shendong Yuan, John Beamond Nicholas, Jingyuan Ma, Kumaraswamy Emayan, Marc Adler
  • Patent number: 10675609
    Abstract: An article of manufacture has an external surface at least partly defined by a material compositionally comprising a polymeric hydrogel that takes up water when wetted. The hydrogel-containing material is effective in reducing soil accumulation on, and/or for reducing soil adhesion to, an article designed for a variety of uses, such as transportation, vehicle safety, storage, recreation, leisure, waste disposal, construction, gardening, or traffic control.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: June 9, 2020
    Assignee: NIKE, INC.
    Inventors: Hossein A. Baghdadi, Caleb W. Dyer, Myron Maurer, Denis Schiller, Jeremy D. Walker, Zachary C. Wright, Marc Adler
  • Publication number: 20200123114
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Application
    Filed: September 27, 2017
    Publication date: April 23, 2020
    Applicant: Blade Therapeutics, Inc.
    Inventors: Brad Owen BUCKMAN, John Beamond NICHOLAS, Shendong YUAN, Marc ADLER, Kumaraswamy EMAYAN, Jingyuan MA
  • Patent number: 10590084
    Abstract: The present technology relates to cyclic keto-amide compounds of general formulae I to XXXII, compositions and kits thereof as calpain modulators and methods useful for the treatment of various diseases or disorders such as fibrotic disease or cancer which are associated or mediated, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is also applicable to cyclic keto-amide compounds which inhibit myofibroblast differentiation.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: March 17, 2020
    Assignee: Blade Therapeutics, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Shendong Yuan, Marc Adler
  • Publication number: 20190194139
    Abstract: The present technology relates to cyclic keto-amide compounds of general formulae I to XXXII, compositions and kits thereof as calpain modulators and methods useful for the treatment of various diseases or disorders such as fibrotic disease or cancer which are associated or mediated, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is also applicable to cyclic keto-amide compounds which inhibit myofibroblast differentiation.
    Type: Application
    Filed: March 8, 2017
    Publication date: June 27, 2019
    Applicant: Blade Therapeutics, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Shendong Yuan, Marc Adler
  • Patent number: 10202378
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: February 12, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Daniel J. Burdick, Terry Crawford, Martin Duplessis, Steven R. Magnuson, Christopher G. Nasveschuk, F. Anthony Romero, Yong Tang, Vickie Hsiao-Wei Tsui, Shumei Wang
  • Patent number: 9884828
    Abstract: The present invention provides compounds having a structure according to Formula I: (I) or a salt or solvate thereof, wherein R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: February 6, 2018
    Assignee: Imago Pharmaceuticals, Inc.
    Inventors: Danielle L. Aubele, Albert W. Garofalo, Simeon Bowers, Anh P. Truong, Xiaocong Michael Ye, Maurizio Franzini, Marc Adler, R. Jeffrey Neitz, Gary Probst
  • Publication number: 20180009805
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.
    Type: Application
    Filed: July 24, 2017
    Publication date: January 11, 2018
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Daniel J. Burdick, Terry Crawford, Martin Duplessis, Steven R. Magnuson, Christopher G. Nasveschuk, Anthony F. Romero, Yong Tang, Vickie Hsiao-Wei Tsui, Shumei Wang
  • Publication number: 20170333406
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: August 2, 2017
    Publication date: November 23, 2017
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • Patent number: 9763922
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 19, 2017
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • Publication number: 20170252722
    Abstract: An article of manufacture has an external surface at least partly defined by a material compositionally comprising a polymeric hydrogel that takes up water when wetted. The hydrogel-containing material is effective in reducing soil accumulation on, and/or for reducing soil adhesion to, an article designed for a variety of uses, such as transportation, vehicle safety, storage, recreation, leisure, waste disposal, construction, gardening, or traffic control.
    Type: Application
    Filed: February 24, 2017
    Publication date: September 7, 2017
    Applicant: NIKE, Inc.
    Inventors: Hossein A. BAGHDADI, Caleb W. DYER, Myron MAURER, Denis SCHILLER, Jeremy D. WALKER, Zachary C. WRIGHT, Marc ADLER
  • Publication number: 20160158207
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 9, 2016
    Applicants: Genentech, Inc., Constellation Pharmaceuticals, Inc.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu